WallStSmart

Merck & Company Inc (MRK)vsRetractable Technologies Inc (RVP)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 176941% more annual revenue ($65.77B vs $37.15M). MRK leads profitability with a 13.6% profit margin vs -16.9%. MRK earns a higher WallStSmart Score of 50/100 (D+).

MRK

Hold

50

out of 100

Grade: D+

Growth: 3.3Profit: 8.0Value: 2.7Quality: 5.0
Piotroski: 3/9Altman Z: 2.30

RVP

Avoid

29

out of 100

Grade: F

Growth: 2.0Profit: 2.0Value: 5.0Quality: 7.5
Piotroski: 5/9Altman Z: 1.23
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKSignificantly Overvalued (-49.3%)

Margin of Safety

-49.3%

Fair Value

$80.88

Current Price

$120.79

$39.91 premium

UndervaluedFair: $80.88Overvalued

Intrinsic value data unavailable for RVP.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$285.64B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
38.6%10/10

Strong operational efficiency at 38.6%

Free Cash FlowQuality
$2.93B8/10

Generating 2.9B in free cash flow

RVP2 strengths · Avg: 10.0/10
Price/BookValuation
0.3x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.0110/10

Conservative balance sheet, low leverage

Areas to Watch

MRK4 concerns · Avg: 3.5/10
P/E RatioValuation
32.6x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Debt/EquityHealth
1.073/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

RVP4 concerns · Avg: 2.3/10
Market CapQuality
$20.95M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-9.0%2/10

ROE of -9.0% — below average capital efficiency

Revenue GrowthGrowth
-13.5%2/10

Revenue declined 13.5%

EPS GrowthGrowth
-66.7%2/10

Earnings declined 66.7%

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bull Case : RVP

The strongest argument for RVP centers on Price/Book, Debt/Equity.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.

Bear Case : RVP

The primary concerns for RVP are Market Cap, Return on Equity, Revenue Growth.

Key Dynamics to Monitor

MRK profiles as a value stock while RVP is a turnaround play — different risk/reward profiles.

RVP carries more volatility with a beta of 1.25 — expect wider price swings.

MRK is growing revenue faster at 4.9% — sustainability is the question.

MRK generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

MRK scores higher overall (50/100 vs 29/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Retractable Technologies Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Retractable Technologies, Inc. designs, develops, manufactures, and markets safety syringes and other medical products for the healthcare industry in the United States, the rest of North and South America, and internationally. The company is headquartered in Little Elm, Texas.

Want to dig deeper into these stocks?